We are live on ! Find out more
INO icon

Inovio Pharmaceuticals
INO

125 hedge funds and large institutions have $196M invested in Inovio Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 34 increasing their positions, 38 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more call options, than puts

Call options by funds: $6.66M | Put options by funds: $4.66M

1% more capital invested

Capital invested by funds: $194M → $196M (+$2.21M)

0.05% more ownership

Funds ownership: 2.9% → 2.95% (+0.05%)

5% less funds holding

Funds holding: 131 → 125 (-6)

11% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 38

31% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 16

Holders
125
Holders Change
-6
Holders Change %
-4.58%
% of All Funds
3.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
34
Reduced
38
Closed
16
Calls
$6.66M
Puts
$4.66M
Net Calls
+$2.01M
Net Calls Change
+$573K

Top Buyers

1
State Street
State Street
Massachusetts
+$4.37M
2
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$2.21M
3
Charles Schwab
Charles Schwab
California
+$1.42M
4
BFA
BlackRock Fund Advisors
California
+$1.35M
5
Invesco
Invesco
Georgia
+$1.17M

Top Sellers

1
EA
Emerald Acquisition
Washington
-$1.43M
2
Axa
Axa
France
-$1.27M
3
EI
EAM Investors
California
-$968K
4
GC
Globeflex Capital
California
-$928K
5
VKH
Virtu KCG Holdings
New York
-$906K
Name Holding Trade Value Shares
Change 		Change in
Stake
RTS
26
Round Table Services
New Jersey
$1.21M – – –
ERSOT
27
Employees Retirement System of Texas
Texas
$1.16M – – –
Swiss National Bank
28
Swiss National Bank
Switzerland
$1.06M – – –
AllianceBernstein
29
AllianceBernstein
Tennessee
$891K – – –
GCP
30
GSA Capital Partners
United Kingdom
$880K +$232K +2,100 +36%
IG
31
ING Group
Netherlands
$803K – – –
Goldman Sachs
32
Goldman Sachs
New York
$776K +$326K +2,951 +74%
Wells Fargo
33
Wells Fargo
California
$765K +$1.77K +16 +0.2%
CS
34
Credit Suisse
Switzerland
$763K -$262K -2,368 -26%
EA
35
Emerald Acquisition
Washington
$752K -$1.43M -12,945 -66%
Citigroup
36
Citigroup
New York
$717K +$168K +1,520 +31%
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$655K +$9.17K +83 +1%
VIA
38
Vident Investment Advisory
Georgia
$591K – – –
AQR Capital Management
39
AQR Capital Management
Connecticut
$582K +$575K +5,208 New
Ohio Public Employees Retirement System (OPERS)
40
Ohio Public Employees Retirement System (OPERS)
Ohio
$526K – – –
Dimensional Fund Advisors
41
Dimensional Fund Advisors
Texas
$511K – – –
ProShare Advisors
42
ProShare Advisors
Maryland
$493K -$88.5K -801 -15%
California Public Employees Retirement System
43
California Public Employees Retirement System
California
$486K -$34K -308 -7%
MLICM
44
Metropolitan Life Insurance Company (MetLife)
New York
$482K -$10.9K -99 -2%
PP
45
Paloma Partners
Connecticut
$430K -$153K -1,387 -27%
Manulife (Manufacturers Life Insurance)
46
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$426K -$3.54K -32 -0.8%
QIM
47
Quantitative Investment Management
Virginia
$423K -$242K -2,192 -37%
D.E. Shaw & Co
48
D.E. Shaw & Co
New York
$413K -$24.4K -221 -6%
NFA
49
Nationwide Fund Advisors
Ohio
$407K – – –
DekaBank Deutsche Girozentrale
50
DekaBank Deutsche Girozentrale
Germany
$380K – – –
1
2
3 4 5

INO Hedge Fund Activity: Q3 2016 in Review

125 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q3 2016, worth a combined $196M — up 1.1% from $194M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of INO and 11 opened new positions — a net loss of 5 holders — while 38 trimmed existing stakes and 34 added.

The largest buyer was State Street, adding an estimated $4.37M. The largest seller was Emerald Acquisition, cutting an estimated $1.43M.

  • 125 institutional investors held Inovio Pharmaceuticals (INO) as of Q3 2016, down from 131 in Q2 2016.
  • Funds reported $196M of Inovio Pharmaceuticals stock for Q3 2016, up 1.1% quarter-over-quarter.
  • 11 funds opened new Inovio Pharmaceuticals positions in Q3 2016 and 16 closed out, a net change of -5 holders.
  • The largest Inovio Pharmaceuticals buyer in Q3 2016 was State Street, an estimated $4.37M added.
  • The largest Inovio Pharmaceuticals seller in Q3 2016 was Emerald Acquisition, an estimated $1.43M sold.

Based on aggregated 13F filings for Q3 2016.